Bristol-Myers Squibb Co
featured
Take a look at some of Wednesday midday movers:
» Read More
More
-
NEW YORK, Feb 25- Michael Weitz was out of options. It typically has taken a decade and $1 billion to bring a new treatment to market.
-
*Tested in genotype 2/ 3 patients who failed prior therapy. Feb 19- Gilead Sciences Inc said its experimental hepatitis C drug sofosbuvir, in a late-stage clinical study, was clearly superior to historical cure rates at both 12 and 16 weeks of treatment in patients who were not helped by prior therapy.
-
Feb 12- A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday. " She said the company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
-
Feb 12- A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday. "We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said.
-
U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.
-
Feb 4- Biotechnology company Gilead Sciences on Monday said two trials of its hepatitis C drug, the centerpiece of its oral hepatitis C treatment program, met their goals in two late-stage studies. The results are expected to be used to support the company's regulatory filing seeking approval in the United States.
-
The Forensic Accounting ETF launches today. The fund spotlights a concept that is often woefully overlooked.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.
-
*Q4 sales $7.28 billion, vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss said the drugmaker faced a tough year, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continued to erode business.
-
*Q4 sales $7.28 billion vs I/B/E/S consensus $7.20 bln. *Q4 core EPS $1.56 vs $1.35, helped by tax adjustment. LONDON, Jan 31- AstraZeneca's new boss warned on Thursday the drugmaker faced a tough year in 2013, with sales expected to fall by a mid-to-high single digit percentage rate as patent expiries continue to erode business.
-
NEW YORK, Jan 30- The slump in Apple Inc's share price from its September high has badly dented the returns of hundreds of mutual funds that had maintained outsized holdings of the stock.
-
Jan 29- Pfizer Inc and Eli Lilly and Co reported better-than-expected fourth-quarter profits as deals, cost cutting and strong sales of new products helped the pharmaceutical companies weather generic competition for once top-selling products.
-
Jan 29- Pfizer Inc and Eli Lilly and Co both reported a better-than-expected fourth-quarter profit as they weathered generic competition for once top-selling products through deals, cost cutting and strong sales of newer products.
-
*Sales $4.19 bln vs Street view $4.12 bln. Jan 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results on Thursday, lifting its shares 2.5 percent, but scaled back its 2013 earnings forecast following setbacks for several of its experimental drugs.
-
*Sales $4.19 bln vs Street view $4.12 bln. Jan 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results on Thursday, lifting its shares 2.7 percent, but scaled back its 2013 earnings forecast following setbacks for several of its experimental drugs.
-
U.S. stock index futures continued to trade mixed Thursday despite a better-than-expected jobless claims report, as disappointing Apple earnings weighed on technology stocks.
-
Jan 24- Bristol-Myers Squibb Co reported better than expected quarterly sales and earnings, fueled by strong sales of newer treatments for leukemia, melanoma and diabetes. Wall Street had expected $4.12 billion. The consensus Wall Street forecast, of $1.83 per share, lies in the middle of that range.
-
Jan 24- Bristol-Myers Squibb Co reported better than expected quarterly sales and earnings, fueled by strong sales of newer treatments for leukemia, melanoma and diabetes. The U.S. drugmaker on Thursday said it earned $925 million, or 56 cents per share, in the fourth quarter. That compared with $852 million, or 50 cents per share, in the year-earlier quarter.
-
LONDON, Jan 23- Britain's national health costs watchdog has recommended Bristol-Myers Squibb and Pfizer's anti-clotting pill Eliquis for preventing strokes in patients with an irregular heartbeat condition called atrial fibrillation.
-
A flood of earnings reports, including major technology and industrial companies, could make or break the stock market’s surprise January rally in the week ahead.